International Journal of Pharmacology and Pharmaceutical Research

ISSN Print: 2664-7184
ISSN Online: 2664-7192
IJPPR 2023; 5(1): 41-44
www.pharmacologyjournals.com
Received: 03-10-2023
Accepted: 08-11-2023

Indrajeet Gandakhe
Student, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Maharashtra, India

Shubhangi Manikpuriya
Assistant Professor, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Maharashtra, India

Dr Gajanan Sanap
Principal, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Maharashtra, India

Corresponding Author:
Indrajeet Gandakhe
Student, Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy, Maharashtra, India

ACE inhibitors acts on renal failure

Indrajeet Gandakhe, Shubhangi Manikpuriya and Dr. Gajanan Sanap

DOI: https://dx.doi.org/10.33545/26647184.2023.v5.i1a.21

Abstract
In individuals suffering from chronic renal illness, heart failure, or hypertension, ACE inhibitors efficiently lower systemic vascular resistance. A significant portion of their long-term renoprotective effects in patients with diabetes and non-diabetic renal illness are likely explained by their antihypertensive efficacy.
ACE inhibition can cause acute renal failure, which is reversible after the drug is stopped, in situations where glomerular filtration is critically dependent on angiotensin II-mediated efferent vascular tone. Sodium depletion increases the positive and negative effects of ACE inhibition on systemic and renal hemodynamic. Consequently, in patients with acute renal failure brought on by ACE inhibitors, sodium repletion helps to restore renal function. Conversely, in individuals whose blood pressure or proteinuria do not respond adequately to treatment, co-treatment with diuretics and salt restriction can increase therapeutic efficacy.

Keywords: Chronic renal illness, hypertension, ace inhibitors, renoprotective effect

Introduction
Renal failure: The Inability of the kidneys to carry out their excretory function, which results in the retention of nitrogenous waste products in the blood, is referred to as renal failure.

Types of Renal failure
- Chronic renal failure
- Acute renal failure

Chronic renal failure
Rodent models of diabetes or reduced renal mass were the first to demonstrate the benefits of ACE inhibitors in the treatment of kidney disease [1].
Chronic renal disease, or CRF for short, is characterized by a continuous decline in kidney function, or, to put it another way, abnormally high serum creatinine levels for longer than three months or a calculated glomerular filtration rate (GFR) of less than 60 milliliters per minute, or 1.73 millimeters. Renal replacement therapy, such as dialysis or kidney transplantation, is frequently required due to a progressive loss of kidney function. End-stage renal disease (ESRD) is the term used to describe the state in which a patient requires renal replacement therapy [2].

Acute renal failure
The syndrome known as ARF is characterized by a sudden (hours to days) decline in glomerular filtration that is typically reversible. Any of the following conditions can be used to diagnose AKI, per the 2012 KDIGO criteria: Urine volume less than 0.5 mL/kg per hour for six hours; (2) creatinine increase to 1.5 times baseline within the last seven days; or (3) a rise in creatinine of 0.3 mg/dL in 48 hours. Since acute kidney injury (AKI) encompasses the whole clinical spectrum from a slight rise in serum creatinine to overt renal failure, it has recently superseded acute renal failure (ARF) [3].

Cases of renal failure
The percentage of adults with chronic kidney disease approaching 15% in many high-income nations [4].

Mostly brought on by hypertensive and diabetic nephropathy, and it presents a significant financial and medical burden [5]. Renal failure and kidney disease are also significant, albeit little-documented, burdens for low- and middle-income nations. Toxins, infectious diseases, and environmental contaminants are considered to be the main causes of acute kidney injury and chronic kidney disease in low-income countries. Middle income nations, like India, that are experiencing swift changes in the economy and epidemiology seem to be bearing two burdens: the prevalence of infectious kidney disease is still high, and rates of hypertension, especially untreated kidney disease, are on the rise [6-7].



Fig 1: cases of renal failure in India

Biosynthesis, storage, release and function of Angiotensin converting enzyme

Synthesis: The main place where ACE is made is in the endothelial cells of blood vessels, particularly those in the lungs. The liver produces angiotensinogen, which is the precursor protein for ACE. Renin is a hormone produced by the kidneys that changes angiotensinogen into angiotensin I in response to a variety of stimuli, including low blood pressure.



Fig 2: synthesis of angiotensin converting enzyme

Storage: Endothelial cells, especially those in the blood vessels and lungs, have ACE on their surface once it has been synthesized.

Release: ACE enters the bloodstream and interacts with its substrates there. Unlike some other enzymes, the release of ACE is usually not controlled by its storage in secretory

vesicles. Rather, endothelial cells' surface has it easily accessible.

Function

Conversation of Angiotensin I to Angiotensin II: The main job of ACE is to change the inactive precursor angiotensin I into angiotensin II. Being a strong vasoconstrictor, angiotensin II causes blood vessels to narrow, which raises blood pressure.

Inactivation of Bradykinin: ACE also deactivates bradykinin, a peptide that stimulates blood vessel dilatation and a vasodilator. This twofold action aids in blood pressure regulation.

Aldosterone Release: The adrenal glands release aldosterone when angiotensin II is present. Blood volume and blood pressure rise as a result of aldosterone's action on the kidneys, which increases the reabsorption of water and salt.

Antiproliferative Effects: Research has demonstrated that ACE inhibits the growth of cells and changes the structure of tissues. Tissue repair and cardiovascular disorders may be impacted by these effects.

Role in Lung Function: Bradykinin and other peptides are metabolized by ACE in the lungs, which affects the tone of local blood vessels.

Blood Pressure Regulation: ACE is essential for controlling blood pressure because it affects vasoconstriction, aldosterone release, and fluid balance [8].

Mechanism of action Ace inhibitors acts on renal failure

Within the renin-angiotensin-aldosterone system (RAAS; media item 1), the angiotensin-converting enzyme (ACE) facilitates the conversion of angiotensin I to angiotensin II. ACE inhibitors are ACE competitive inhibitors that stop angiotensin I from becoming angiotensin II. When inhibited, angiotensin II's strong vasoconstrictor effects can lower blood pressure by widening blood vessels and lowering the release of aldosterone [9].

To fully appreciate the therapeutic effects of ACE inhibitors and comprehend why the RAAS hormonal system is a target for hypertensive therapy, it is imperative to have a thorough understanding of this system's function. Prorenin is first synthesized by afferent arteriole juxtaglomerular cells and is subsequently actively cleaved to renin. Renin then cleaves the angiotensinogen that the liver produces to create angiotensin I. ACE transforms the angiotensin I molecule into angiotensin II. One molecule that significantly affects a number of systems is angiotensin II. Angiotensin II first causes vasoconstriction, which raises blood pressure throughout the body [10].

Angiotensin II triggers the production of aldosterone by the adrenal cortex and antidiuretic hormone by the pituitary. By internal mineralocorticoid receptor activity, aldosterone causes sodium reabsorption, which in turn causes water reabsorption [11].

The production of aquaporin-2 channels in the collecting duct is increased by antidiuretic hormone, resulting in the selective reabsorption of water. Adverse cardiac remodeling is caused by the actions of aldosterone and angiotensin II. ACE inhibitors work by lowering the levels of aldosterone and angiotensin-II in the heart. This prevents adverse cardiac remodelling [12].



Fig 3: Mechanism of action of ace inhibitors

Table 1: Classification of ace inhibitors acts on renal failure: [15], [16]

Angiotensin Inhibitors type 1:	Angiotensin Inhibitors type 2
Losartan	Losartan
Azilsartan	Valsartan
Candesartan	Irbesartan
Eprosartan	Candesartan
Irbesatan	Telmisartan
Omesartan	Eprosartan
Telmisartan	
Valisartan	

Table 2: Latest approved drug ace inhibitors act on renal failure:

Name of drug.	Captopril	Enalapril	Lisinopril	Benazepril	Qynapril	Ramipril	Trandolapril	Moexipril
Zinc ligand	Sulfhydril	Carboxyl	Carboxyl	Carboxyl	Carboxyl	Carboxyl	Carboxyl	Carboxyl
Pro drug	No	Yes	No	Yes	Yes	Yes	Yes	Yes
Tmax active drug. H	0.7-0.9	2-8	6-8	1-2	2	3	4-10	1.5
t1/2 active drug h	1.7	11	12	10-11	1.9-2.5,25 terminal	Triphasic4.9-18>50	15-24 terminal	2-9
Route of elimination	Kidney	Kidney	Kidney	Kidney	Kidney	Kidney	Kidney, liver	Kidney
Dosage range, mg	6.25-300	2.5-40	5-40	5-80	5-80	1.25-20	1-8	7.5-30
F. %1	75-91	60	6-60	>37	>60	50-60	70	13

*F indicate bioavilability of drug, latest approved drug in United States

Conclusion

Since the release of these medications, there has been a noticeable shift in the understanding of the renal risk-benefit ratio of ACE inhibitors. Early research on ACE inhibition's effects on the kidneys also shed light on the physiology of the RAAS. The success of later research outlining the advantageous effects of ACE inhibitors in cardiac and renal disease has been aided by this understanding. Although ACE inhibition may lead to reversible impairment of renal function, patients with heart failure, diabetes mellitus, and/or chronic renal failure who are most at risk for adverse effects on their kidneys can also benefit most from ACE inhibition. As a result, rather than stopping ACE inhibitors in these patients, treatment should be carefully titrated. This makes it possible to reduce treatment risks and, as a result, positively impact each patient's risk-benefit ratio.

Acknowledgement

The author would like to express sincere gratitude to the management of Late Bhagirathi Yashwantrao Pathrikar College of Pharmacy for their continuous support and encouragement in this work.

Reference

1. Zatz R, Dunn BR, Meyer TW, *et al*. Prevention of diabetic glome Rulopathy by pharmacological amelioration of glomerular capillary Hypertension. J Clin Invest. 1986;77:1925-1930.
2. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005 Nov;16(11):3365-70.
3. Luo X, Jiang L, Du B, Wen Y, Wang M, Xi X. Beijing Acute Kidney Injury Trial (BAKIT) workgroup. A comparison of different diagnostic criteria of acute kidney injury in critically ill patients. Crit Care. 2014 Jul 08;18(4):R144.
4. Coresh J, Selvin E, Stevens LA, *et al*. Prevalence of chronic kidney Disease in the United States. JAMA 2007;298:2038-47.
5. Kerr M, Bray B, Medcalf J, O'Donoghue DJ, Matthews B. Estimating the fi nancial cost of hronic kidney disease to the NHS In England. Nephrol Dial Transplant. 2012;27(suppl 3):73-80.
6. Jha V, Garcia-Garcia G, Iseki K, *et al*. Chronic kidney disease: Global dimension and perspectives. Lancet. 2013;382:260-72.
7. Zhang L, Wang F, Wang L, *et al*. Prevalence of chronic kidney Disease in China: A cross-sectional survey. Lancet. 2012;379:815-22.
8. ACE Inhibitors: A comprehensive review Pradeep Kumar Arora and Ashish Chauhan, Department of Pharmacy, Lovely Professional University, Phagwara, Punjab, India.
9. Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q, *et al*. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2018 Nov 14;11(11):CD008170.
10. Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017 Oct;94:317-325.
11. Silva P, Brown RS, Epstein FH. Adaptation to potassium. Kidney Int. 1977 Jun;11(6):466-75.
12. Yee AH, Burns JD, Wijdicks EF. Cerebral salt wasting: pathophysiology, diagnosis, and treatment. Neurosurg Clin N Am. 2010 Apr;21(2):339-52.
13. European medicines agency.
14. Angiotensin-Converting Enzyme (ACE) Inhibitors Cleveland Clinic. Retrieved 2022-11-05.
15. Singh KD, Sadashiva S Karnik. Angiotensin Type 1 Receptor Blockers in Heart Failure, HHS public Access page no.3-6
16. Burnier M. Angiotensin II Type 1 Receptor Blockers" cardiovascular drugs Page no.3.